Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection

Scandinavian Journal of Gastroenterology

Volumn 39, Issue 7, 2004, Pages 650-656

  Bendet, N ^a   Scapa, E ^a   Cohen, O ^a   Bloch, O ^a   Aharoni, D ^a   Ramot, Y ^a   Weiss, M ^a   Halevi, A ^a   Rapoport, M J ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

Crohn disease; GLP 1; Glucose; HOMA; Insulin; Insulin resistance; ISI

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; CROHN DISEASE; DIET RESTRICTION; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH STATUS; HUMAN; ILEUM DISEASE; ILEUM RESECTION; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN SECRETION;

ADULT; AGED; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CROHN DISEASE; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; ILEITIS; ILEUM; INSULIN; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS;

EID: 3142709603     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520410004839     Document Type: Article

References (45)

1. Crohn BB, Ginzburg L, Ginzburg L, Oppenheimer GD. Regional ileitis. A pathologic and clinical entity. JAMA 1932;99:1323-9.
2. Janowitz HD. Crohn's disease - 50 years later. N Engl J Med 1981;304:1600-2.
3. Mayberry JF, Rhodes J. Epidemiological aspects of Crohn's disease: a review of the literature. Gut 1984;25:886-99.
4. Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn's disease. Ann Surg 1991;214:230-8.
5. Ebert R. Gut signals for islet hormone release. Eur J Clin Invest 1990;20 Suppl 1:S20-S6.
6. Debas HT. Peripheral regulation of gastric secretion. In: Johnson LR, editor. Physiology of the gastrointestinal tract. 2nd ed. New York: Raven Press; 1987. p. 931-45.
7. Solomon TE. Control of exocrine pancreatic secretion. In: Johnson, LR, editor. Physiology of the gastrointestinal tract. 2nd ed. New York: Raven Press; 1987. p. 1173-208.
8. Kosaka T, Lim RKS. Demonstration of the humoral agent in fat inhibition of gastric secretion. Proc Soc Exp Biol Med 1980;27: 890-91.
9. Harper AA, Hood AJC, Mushens J, Smy JR. Pancreotone, an inhibitor of pancreatic secretion in extracts of ileal and colonic mucosa. J Physiol (London) 1979;292:455-67.
10. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983;302:716-8.
11. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature 1983;304:368-71.
12. White JW, Saunders GF. Structure of the human glucagon gene. Nucleic Acids Res 1986;14:4683-90.
13. Lopez LC, Frazier ML, Su CJ, [cite 6 authors] et al. Mammalian pancreatic preproglucagon contains three glucagon-related peptides. Proc Natl Acad Sci USA 1983;80:5485-9.
14. Heinrich G, Gros P, Habener JF. Glucagon gene sequence-four of six exons encode separate functional domains of rat preproglucagon. J Biol Chem 1984;259:14082-7.
15. Seino S, Welsh M, Bell GI, [cite 6 authors] et al. Mutations in the guinea pig preproglucagon gene are restricted to a specific portion of the prohormone sequence. FEBS Lett 1986;203:25-30.
16. Nishi M, Steiner DF. Cloning of complementary DNAs encoding islet amyloid polypeptide, insulin and glucagon precursors from a new world rodent, the degu, Octodon degus. Mol Endocrinol 1990;14:1192-8.
17. Novac U, Wilks A, Buell G, McEwen S. Identical mRNA for preproglucagon in pancreas and gut. Eur J Biochem 1987;164: 553-8.
18. Ørskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon like peptide GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from the pig small intestine, but not pancreas. Endocrinology 1986;119: 1467-75.
19. Mojosov S, Heinrich G, Wilson IB, [cite 6 authors] et al. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 1986;261:11880-9.
20. Ørskov C, Bersani M, Johnson AH, Hojrup P, Holst JJ. Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J Biol Chem 1989;264:12826-9.
21. Ørskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992;35:701-11.
22. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992;22:283-91.
23. Varndell IM, Bishop AE, Shkiri KL, Uttenthal LO, Bloom SR, Polak JM. Localization of glucagons-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry. L Histochem Cytochem 1985;33:1080-6.
24. Ørskov C, Holst JJ, Seier Poulsen S, Kirkegaard P. Pancreatic and intestinal processing of proglucagon in man. Diabetologia 1987;30:874-1.
25. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon like peptide-1 in humans. Diabetes 1994;43:535-9.
26. Elhai D, Meneilly GS, Scalter A, Wong G, McAloon-Dyke M, Mojsov S, et al. The insulinotropic effect of GIP: a dose response comparison to glucagon-like peptide-1 (7-37) amine (GLP). Digestion 1990;46 Suppl 1:28.
27. Fehmann HC, Göke R, Göke B, Arnold R. Priming with GLP-1 (7-36) amide, GIP and CCK-8 enhances glucose-induced insulin secretion from the isolation perfused rat pancreas. Digestion 1990;46 Suppl 1:32-3.
28. Mojosov S, Weir GC, Habner JF. Insulinotropin: glucagons-like peptide 1 (7-36) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987;79:616-9.
29. Hensen L, Deacon CF, Ørskov C, Holst JJ. Glucagon-like peptide-1- (7-36) amide is transformed to glucagon-like peptide-1- (9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999;140:5356-63.
30. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide 1 (7-36) amide and glucose dependent insuloinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24 h secretion patterns. J Endocrinol 1993;138:159-6.
31. Herrmann C, Göke R, Richter G, et al. Glucagon-like peptide-1 and glucose dependent insulin releasing polypeptide plasma levels in response to nutrients. Digestion 1995;56:117-6.
32. Robertson MD, Livesey G, Morgan LM, Hampton SM, Mathers JC. The influence of the colon on postprandial glucagons-like peptide-1 (7-36) amide concentration in man. J Endocrinol 1999; 161:25-31.
33. Palnaes Hansen C, Andreasen JJ, Holst JJ. The release of gastric inhibitory peptide, glucagon-like peptide-1 and insulin after oral glucose test in colectomized subjects. Scand J Gastroenterol 1997;32:473-7.
34. Printz H, Reiter S, Samadi N, Ebrahimsade S, Kirchner R, Arnold R, et al. GLP-1 release in man after lower large bowel resection of intrarectal glucose administration. Digestion 1998; 59:689-95.
35. Jeppesen PB, Hartmann B, Thulesen J, Hansen BS, Holst JJ, Poulsen SS, et al. Elevated plasma glucagons-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon. Gut 2000;47:370-6.
36. Nauck MA, Siemsgluss J, Ørskov C, Holst JJ. Release of glucagon-like peptide 1 (GLP-1 (7-36 amide)), Gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections. Z Gastroenterol 1996; 34:159-66.
37. Harvey RF, Bradshaw MJ. A simple index of Crohn's disease activity. Lancet 1980;1 (8167):514.
38. Harvey RF, Bradshaw MJ. Measuring Crohn's disease activity. Lancet 1980;1 (8178):1134-5.
39. Punjabi NM, Sorkin JD, Katzel LI, Goldberg AP, Schwartz AR, Smith PL. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Care Med 2002; 165:677-82.
40. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-45.
41. Shiloah E, Witz S, Abramovitch Y, Cohen O, Buchs A, Ramot Y, et al. Effect of acute psychotic stress reaction in non-diabetic patients on beta cell function and insulin sensitivity. Diabetes Care 2003;26:1462-7.
42. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
43. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-70.
44. Dixon WJ. BMDP Statistical software (1992). University of California Press.
45. SAS Institute Inc. (1989) SAS/STAT User's guide: version 6, 4th ed., vol. 2, Cary NC: SAS Institute Inc.